Legal & General Group Plc boosted its holdings in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 7.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,415,969 shares of the medical research company’s stock after acquiring an additional 309,200 shares during the quarter. Legal & General Group Plc’s holdings in Edwards Lifesciences were worth $376,461,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter valued at about $25,000. Kohmann Bosshard Financial Services LLC bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $28,000. Rakuten Securities Inc. increased its stake in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares during the period. Hantz Financial Services Inc. increased its stake in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares during the period. Finally, Dorato Capital Management bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $29,000. Institutional investors own 79.46% of the company’s stock.
Insider Transactions at Edwards Lifesciences
In other news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,816,861.34. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the transaction, the vice president owned 21,266 shares in the company, valued at $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 82,684 shares of company stock worth $6,799,579. Corporate insiders own 0.31% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Edwards Lifesciences
Edwards Lifesciences Price Performance
Shares of Edwards Lifesciences stock opened at $87.58 on Wednesday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $50.43 billion, a price-to-earnings ratio of 46.59, a P/E/G ratio of 2.15 and a beta of 0.87. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $87.93. The firm’s 50-day moving average price is $81.56 and its two-hundred day moving average price is $82.94.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
